Table 1.
Demographic and pretreatment clinical characteristics
| Group 1 | Group 2 | p value | |
|---|---|---|---|
| cCR | pCR | ||
| n patients (%) | 26 (54.2) | 22 (45.8) | |
| Gender (M/F) | 13/13 | 8/14 | |
| Age (years), median (range) | 59 (32–82) | 55 (26–73) | 0.2975 |
| Distance from anal verge (cm), mean (range) | 5 (1–12) | 7 (2–12) | 0.32 |
| T1–2, n (%) | 8 (31) | 4 (18) | 0.5035 |
| T3–4, n (%) | 18 (69) | 18 (82) | 0.5035 |
| cStage III (N+), n (%) | 10 (38) | 16 (72) | 0.04 |
| CRM+, n (%) | 7 (27) | 13 (59) | 0.0515 |
| EMVI+, n (%) | 4 (15) | 11 (50) | 0.0235 |
| LPLN+, n (%) | 5 (19) | 3 (14) | 0.8969 |
| CEA, > 5 ng/dl, n (%) | 3 (11) | 4 (18) | 0.8108 |
| Induction XELOX 3 courses, n (%) | 6 (23) | 5 (23) | 0.7521 |
| Median follow-up—months (range) | 47 (6–94) | 49.5 (3–112) | 0.7848 |
cCR clinical complete response, pCR pathological complete response, F female, M male, N+ lymph nodes suspected of malignancy, CRM+ circumferential resection margin involved, EMVI + extramural vascular invasion, LPLN lateral pelvic lymph nodes, CEA carcinoembryonic antigen, NS not significant